NCT01531790View on ClinicalTrials.gov

A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Carboplatin

d1, AUC 5, i.v.

DRUG

Pemetrexed

d1, 500 mg/m2, i.v.

DRUG

Endostar

d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.

DRUG

Centrum

1 tablet/day

Trial Locations (1)

Unknown

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY